MX363119B - Composicion farmaceutica. - Google Patents

Composicion farmaceutica.

Info

Publication number
MX363119B
MX363119B MX2014013091A MX2014013091A MX363119B MX 363119 B MX363119 B MX 363119B MX 2014013091 A MX2014013091 A MX 2014013091A MX 2014013091 A MX2014013091 A MX 2014013091A MX 363119 B MX363119 B MX 363119B
Authority
MX
Mexico
Prior art keywords
insulin
subject
compound
combination
administration
Prior art date
Application number
MX2014013091A
Other languages
English (en)
Spanish (es)
Other versions
MX2014013091A (es
Inventor
Johansen Thue
Mersebach Henriette
Axelsen Mads
Lange Martin
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of MX2014013091A publication Critical patent/MX2014013091A/es
Publication of MX363119B publication Critical patent/MX363119B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MX2014013091A 2012-05-01 2013-05-01 Composicion farmaceutica. MX363119B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12166252 2012-05-01
EP12166251 2012-05-01
US201261641540P 2012-05-02 2012-05-02
US201261641544P 2012-05-02 2012-05-02
PCT/EP2013/059073 WO2013164375A1 (en) 2012-05-01 2013-05-01 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
MX2014013091A MX2014013091A (es) 2014-12-08
MX363119B true MX363119B (es) 2019-03-11

Family

ID=49514218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014013091A MX363119B (es) 2012-05-01 2013-05-01 Composicion farmaceutica.

Country Status (9)

Country Link
US (1) US9884094B2 (enExample)
EP (1) EP2844274B1 (enExample)
JP (1) JP6262206B2 (enExample)
AU (1) AU2013255880B2 (enExample)
BR (1) BR112014026442A8 (enExample)
CA (1) CA2872083A1 (enExample)
MX (1) MX363119B (enExample)
RU (1) RU2670106C2 (enExample)
WO (1) WO2013164375A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
CN105188736A (zh) * 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
WO2016001185A1 (en) * 2014-07-02 2016-01-07 Novo Nordisk A/S Dosage regimen for the treatment of diabetes
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
WO2025104600A1 (en) * 2023-11-15 2025-05-22 Ambio, Inc. Insulin analogs for the treatment of human metabolic disorder and disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
EP1132404A3 (en) 1993-09-17 2002-03-27 Novo Nordisk A/S Acylated insulin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
CA2531988C (en) 2003-08-05 2016-06-28 Novo Nordisk A/S Novel insulin derivatives
DK2275439T3 (da) 2003-08-05 2014-05-12 Novo Nordisk As Hidtil ukendte insulinderivater
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
EP2015770B1 (en) 2006-05-09 2012-09-26 Novo Nordisk A/S Insulin derivative
JP5552046B2 (ja) 2007-06-13 2014-07-16 ノボ・ノルデイスク・エー/エス インスリン誘導体を含有する薬学的製剤
RU2495131C2 (ru) * 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
JP4959005B2 (ja) * 2008-10-30 2012-06-20 ノボ・ノルデイスク・エー/エス 毎日の注射頻度より少ないインスリン注射での真性糖尿病の治療
PL2632478T3 (pl) * 2010-10-27 2020-03-31 Novo Nordisk A/S Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu

Also Published As

Publication number Publication date
AU2013255880A1 (en) 2014-10-16
BR112014026442A8 (pt) 2018-01-16
JP2015517458A (ja) 2015-06-22
RU2014147674A (ru) 2016-06-27
RU2670106C2 (ru) 2018-10-18
AU2013255880B2 (en) 2017-07-20
CA2872083A1 (en) 2013-11-07
EP2844274A1 (en) 2015-03-11
EP2844274B1 (en) 2019-03-20
US9884094B2 (en) 2018-02-06
US20150126439A1 (en) 2015-05-07
JP6262206B2 (ja) 2018-01-17
BR112014026442A2 (pt) 2017-06-27
WO2013164375A1 (en) 2013-11-07
MX2014013091A (es) 2014-12-08

Similar Documents

Publication Publication Date Title
MX363119B (es) Composicion farmaceutica.
PH12019500517A1 (en) Long-acting formulations of insulins
PH12014500922A1 (en) Insulinotropic peptide derivative wherein its n-terminal amino acid is modified
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
MX2022004041A (es) Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos.
MX375745B (es) Composicion para el tratamiento de la diabetes que comprende conjugado de analogo de insulina de accion prolongada y conjugado de peptido insulinotropico de accion prolongada.
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
EP4434350A3 (en) Feed additive composition
MY183793A (en) Pharmaceutical compositions
NZ714273A (en) Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof
EP4613284A3 (en) Treatment of diabetes mellitus by long-acting formulations of insulins
WO2011087835A3 (en) Novel compositions and methods for treating inflammatory bowel disease and airway inflammation
NZ602380A (en) Peptides for vaccine against birch allergy
AU2012207301A8 (en) Apolipoprotein AIV as an antidiabetic peptide
MX342417B (es) Composicion antioxidante para reducir el estres oxidativo atribuible al tratamiento con farmacos anticonceptivos hormonales.
WO2013084070A3 (en) Salmonella vaccine proteins
WO2014018763A3 (en) Method of treating type i diabetes using apolipoprotein aiv
NZ707168A (en) Pharmaceutical composition of insulins
WO2011163321A3 (en) Composition and method of treating lipid encapsulated virus infections
BR112013000296A2 (pt) agentes terapêuticos 976
HK1223834A1 (zh) 具有生物学活性的胰岛素衍生物
WO2012025831A3 (en) Salmonella vaccine proteins
RU2010126053A (ru) Применение аналогов соматостатина при менингиоме
HK1229209A1 (en) Method and products for enhancing cellular uptake of drug and dietary supplements
IN2013MU01156A (enExample)